We are live on ! Find out more
NTLA icon

Intellia Therapeutics

141 hedge funds and large institutions have $430M invested in Intellia Therapeutics in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $1.43M

5.23% more ownership

Funds ownership: 67.37%72.6% (+5.2%)

5% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 40

10% less funds holding

Funds holding: 157141 (-16)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

42% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 36

48% less capital invested

Capital invested by funds: $833M → $430M (-$403M)

Holders
141
Holders Change
-16
Holders Change %
-10.19%
% of All Funds
3.14%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
21
Increased
42
Reduced
40
Closed
36
Calls
$2.21M
Puts
$1.43M
Net Calls
+$777K
Net Calls Change
+$4.25M
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$1.75M -$1.19M -64,000 -33%
Allianz Asset Management
27
Allianz Asset Management
Germany
$1.75M +$125K +6,738 +6%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.68M -$152K -8,200 -6%
CS
29
Candriam SCA
Luxembourg
$1.64M
PIM
30
Platinum Investment Management
Australia
$1.46M +$965K +51,941 +94%
PP
31
PDT Partners
New York
$1.2M +$316 +17 +0%
GAM
32
Greenwoods Asset Management
Cayman Islands
$1.13M -$4.99M -268,500 -76%
TA
33
Teachers Advisors
New York
$1.1M
Creative Planning
34
Creative Planning
Kansas
$1.06M -$6.67K -359 -0.5%
Squarepoint
35
Squarepoint
New York
$1.03M +$799K +42,999 +132%
WM
36
WS Management
Florida
$994K -$877K -47,202 -39%
First Trust Advisors
37
First Trust Advisors
Illinois
$919K -$1.73M -92,981 -58%
EWM
38
Elmwood Wealth Management
California
$841K -$68.9K -3,705 -6%
GIM
39
Granahan Investment Management
Massachusetts
$830K -$400K -21,525 -26%
AllianceBernstein
40
AllianceBernstein
Tennessee
$803K
Millennium Management
41
Millennium Management
New York
$769K +$1.05M +56,355 New
TCIM
42
TIAA CREF Investment Management
New York
$734K -$33.8K -1,820 -3%
CSS
43
Cubist Systematic Strategies
Connecticut
$733K +$895K +48,175 +877%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$710K +$22.5K +1,209 +2%
SAMH
45
Shanda Asset Management Holdings
British Virgin Islands
$664K +$904K +48,657 New
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$657K +$336K +18,050 +60%
Balyasny Asset Management
47
Balyasny Asset Management
Illinois
$640K +$872K +46,911 New
Neuberger Berman Group
48
Neuberger Berman Group
New York
$633K -$502K -26,981 -37%
Swiss National Bank
49
Swiss National Bank
Switzerland
$580K
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$483K -$113K -6,100 -15%

NTLA Hedge Fund Activity: Q4 2018 in Review

141 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2018, worth a combined $430M — down 48% from $833M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of NTLA and 21 opened new positions — a net loss of 15 holders — while 40 trimmed existing stakes and 42 added.

The largest buyer was Ontario Teachers' Pension Plan Board, opening a new position worth an estimated $30.9M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $15.7M sold.

  • 141 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2018, down from 157 in Q3 2018.
  • Funds reported $430M of Intellia Therapeutics stock for Q4 2018, down 48% quarter-over-quarter.
  • 21 funds opened new Intellia Therapeutics positions in Q4 2018 and 36 closed out, a net change of -15 holders.
  • The largest Intellia Therapeutics buyer in Q4 2018 was Ontario Teachers' Pension Plan Board, an estimated $30.9M added.
  • The largest Intellia Therapeutics seller in Q4 2018 was Farallon Capital Management, an estimated $15.7M sold.

Based on aggregated 13F filings for Q4 2018.